188812-95-5

Basic information

• Product Name: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID
• Synonyms: DL-3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID;3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID;RARECHEM AK HW 0006;3-AMINO-3-(3,5-DICHLOROPHENYL)PROPANOIC ACID
• CAS NO: 188812-95-5
• Molecular Formula: C₉H₉Cl₂NO₂
• Molecular Weight: 234.08
• Mol File: 188812-95-5.mol

Chemical Properties

• Boiling Point: 358.888 °C at 760 mmHg
• Flash Point: 170.85 °C
• Appearance: /
• Density: 1.448 g/cm³
• CAS DataBase Reference: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID(188812-95-5)
• EPA Substance Registry System: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID(188812-95-5)

Safety Data

• Hazardous Substances Data: 188812-95-5(Hazardous Substances Data)

Usage

Uses

Due to the limited information available on 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID, it is difficult to provide a comprehensive list of its applications. However, based on its chemical structure and properties, it can be inferred that it may have potential uses in various industries, such as:
Used in Pharmaceutical Industry:
3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID could be used as an intermediate in the synthesis of pharmaceutical compounds, given its unique combination of an amino group, a carboxylic acid group, and a dichlorobenzene moiety. These functional groups may allow for the formation of various derivatives with potential therapeutic applications.
Used in Chemical Research:
3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID may serve as a starting material or a reagent in chemical research, particularly in the field of organic synthesis. Its distinct structural features could be exploited to explore new reaction pathways or to develop novel synthetic methods.
Used in Material Science:
3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID's dichlorobenzene moiety and its ability to form amide linkages may make it a candidate for the development of new materials with specific properties, such as polymers or coatings with tailored characteristics for use in various applications.

Upstream product

• 141-82-2 malonic acid 
• 10203-08-4 3,5-dichlorobenzaldehyde 

Downstream Products

• 188814-26-8 3-[N-(9H-fluoren-9-ylmethoxycarbonyl)-amino]-3-(3,5-dichloro)-phenylpropionic acid 
• 147524-80-9 3-amino-3-(3,5-dichloro-phenyl)-propionic acid ethyl ester 
• 748132-67-4 ethyl (R)-3-amino-3-(3,5-dichlorophenyl)propanoate 
• 1080673-41-1 (S)-3-amino-3-(3,5-dichlorophenyl)propanoic acid 
• 406692-08-8 3-(2-tert-butoxycarbonylamino-acetylamino)-3-(3,5-dichloro-phenyl)-propionic acid methyl ester 

Relevant articles and documents

PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS

The disclosure relates to compounds of formula I: Formula I which inhibit αv-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS

The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS

The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents

Antagonism of αvβ6 is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an αvβ3 antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved αvβ6 activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan αv antagonists having ca. 100 nM potency against αvβ3, αvβ5, αvβ6, and αvβ8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC50 values between the integrins in question) for αvβ3 and αvβ5.

An efficient new enzymatic method for the preparation of β-aryl-β-amino acid enantiomers

An efficient synthesis of β-aryl-β-amino acid enantiomers has been developed via the lipase-catalysed enantioselective hydrolysis of the corresponding racemic ethyl esters in an organic solvent. High enantioselectivities (E >100) were observed when the lipase PS-catalysed reactions were performed with H2O (0.5 equiv) in diisopropyl ether at 45 °C. The products could be easily separated and were obtained in good yields of ≥40%.

R-Isomers of Arg-Gly-Asp (RGD) mimics as potent αvβ3 inhibitors

The integrin αvβ3, vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the

Nanomolar small molecule inhibitors for ανβ6, ανβ5, and ανβ3 integrins

Integrin adhesion receptors frequently recognize a core amino acid sequence, Arg-Gly-Asp, in their target ligands. Inhibitors with the ability to inhibit one or a small subset of such RGD-dependent integrins have been invaluable in defining their biological function. Here, we have characterized low molecular weight inhibitors for their ability to specifically inhibit ανβ6 integrin, a fibronectin/tenascin receptor. As of yet, no nonpeptidic inhibitor of ανβ6 was known. New peptidomimetic and nonpeptidic compounds were examined in isolated integrin binding assays and in cell adhesion assays for their ability to block ανβ6, ανβ3, ανβ5, and αIIbβ3 integrins. The compounds are based on an aromatically substituted β amino acid or glutaric acid derivative as an acidic center and an aminopyridyl or guanidyl residue as a basic mimetic. We found several classes of inhibitors with different selectivities, especially mono- or biselectivity on the αν-integrins ανβ6 and ανβ3, and nanomolar activity. Furthermore, nearly all compounds are inactive on αIIbβ3. Compound 11 is the first specific, peptidomimetic inhibitor of the ανβ6 integrin receptor.

Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists

The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.